首页 > 最新文献

AIDS最新文献

英文 中文
Doxycycline as postexposure prophylaxis for STI prevention: implementation and care continuum in key populations. 多西环素作为性传播感染预防的暴露后预防:关键人群的实施和护理连续性。
IF 3.1 2区 医学 Q3 IMMUNOLOGY Pub Date : 2026-02-01 Epub Date: 2025-12-24 DOI: 10.1097/QAD.0000000000004396
Philip A Chan, Michaela A Maynard
{"title":"Doxycycline as postexposure prophylaxis for STI prevention: implementation and care continuum in key populations.","authors":"Philip A Chan, Michaela A Maynard","doi":"10.1097/QAD.0000000000004396","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004396","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"40 2","pages":"256-259"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial. 从一项随机试验中,doravirine/islatravir在有大量治疗经验的HIV-1患者中的有效性和安全性
IF 3.1 2区 医学 Q3 IMMUNOLOGY Pub Date : 2026-02-01 Epub Date: 2025-10-01 DOI: 10.1097/QAD.0000000000004367
Andrew Carr, Rosie Mngqibisa, Ilsiyar Khaertynova, Princy N Kumar, Shariq Haider, Ying Zhang, Todd Correll, Ernest Asante-Appiah, Wayne Greaves

Objective: This study evaluated the efficacy (day 8) and safety (week 49) of doravirine/islatravir (DOR/ISL; 100 mg/0.75 mg) plus baseline antiretroviral therapy (ART) and optimized background therapy (OBT) in heavily treatment-experienced (HTE) adults living with detectable HIV-1 RNA.

Design and methods: HTE adults with confirmed plasma viral load more than 500 copies/ml receiving a stable ART regimen for at least 3 months were randomly assigned 1 : 2 : 1 : 1 to receive once-daily ISL alone, DOR alone, DOR/ISL, or matching placebo for 7 days; at day 8, baseline ART was optimized and all participants received DOR/ISL and OBT through week 49. The primary efficacy endpoint was percentage of participants receiving DOR/ISL achieving at least 0.5 log 10 decline in viral load from baseline (day 1) to day 8. Secondary efficacy endpoints included HIV-1 RNA levels and CD4 + T-cell counts through week 49.

Results: Thirty-five of the planned 100 participants were enrolled; most were White (57.1%) and men (77.1%) with median age of 50 years. From days 1 to 8, an at least 1.0 log 10 decrease in HIV-1 RNA was achieved in 85.7% of the DOR/ISL group compared with 0 in the placebo group. At week 49, HIV-1 RNA less than 50 copies/ml was achieved in 22 participants (71%) and the mean increase in CD4 + T-cell count was 87 cells/μl. Adverse events were reported in 29 participants (82.9%) through week 49; 9 (25.7%) were considered related to DOR/ISL.

Conclusion: DOR/ISL plus OBT improved HIV-1 suppression in HTE adults living with HIV-1 and was generally well tolerated.

Clinicaltrialsgov: NCT04233216.

目的:本研究评估了doravirine/islatravir (DOR/ISL 100 mg/0.75 mg)联合基线抗逆转录病毒治疗(ART)和优化背景治疗(OBT)在重度治疗经历(HTE)携带可检测HIV-1 RNA的成人中的疗效(第8天)和安全性(第49周)。设计和方法:接受稳定抗逆转录病毒治疗≥3个月且确认血浆病毒载量为500copies /mL的HTE成人按1:2:1:1随机分配,分别接受每日1次ISL、DOR、DOR/ISL或匹配安慰剂治疗7天;在第8天,基线ART得到优化,所有参与者在第49周接受DOR/ISL和OBT。主要疗效终点是接受DOR/ISL治疗的参与者从基线(第1天)到第8天病毒载量下降≥0.5 log10的百分比。次要疗效终点包括第49周的HIV-1 RNA水平和CD4+ t细胞计数。结果:计划的100名参与者中有35人入选;以白人(57.1%)和男性(77.1%)居多,中位年龄50岁。从第1天到第8天,DOR/ISL组中85.7%的HIV-1 RNA降低≥1.0 log10,而安慰剂组为0%。结论:DOR/ISL加OBT改善了HIV-1感染成人HTE患者的HIV-1抑制,并且通常耐受性良好。Clinicaltrialsgov: NCT04233216。
{"title":"Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial.","authors":"Andrew Carr, Rosie Mngqibisa, Ilsiyar Khaertynova, Princy N Kumar, Shariq Haider, Ying Zhang, Todd Correll, Ernest Asante-Appiah, Wayne Greaves","doi":"10.1097/QAD.0000000000004367","DOIUrl":"10.1097/QAD.0000000000004367","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluated the efficacy (day 8) and safety (week 49) of doravirine/islatravir (DOR/ISL; 100 mg/0.75 mg) plus baseline antiretroviral therapy (ART) and optimized background therapy (OBT) in heavily treatment-experienced (HTE) adults living with detectable HIV-1 RNA.</p><p><strong>Design and methods: </strong>HTE adults with confirmed plasma viral load more than 500 copies/ml receiving a stable ART regimen for at least 3 months were randomly assigned 1 : 2 : 1 : 1 to receive once-daily ISL alone, DOR alone, DOR/ISL, or matching placebo for 7 days; at day 8, baseline ART was optimized and all participants received DOR/ISL and OBT through week 49. The primary efficacy endpoint was percentage of participants receiving DOR/ISL achieving at least 0.5 log 10 decline in viral load from baseline (day 1) to day 8. Secondary efficacy endpoints included HIV-1 RNA levels and CD4 + T-cell counts through week 49.</p><p><strong>Results: </strong>Thirty-five of the planned 100 participants were enrolled; most were White (57.1%) and men (77.1%) with median age of 50 years. From days 1 to 8, an at least 1.0 log 10 decrease in HIV-1 RNA was achieved in 85.7% of the DOR/ISL group compared with 0 in the placebo group. At week 49, HIV-1 RNA less than 50 copies/ml was achieved in 22 participants (71%) and the mean increase in CD4 + T-cell count was 87 cells/μl. Adverse events were reported in 29 participants (82.9%) through week 49; 9 (25.7%) were considered related to DOR/ISL.</p><p><strong>Conclusion: </strong>DOR/ISL plus OBT improved HIV-1 suppression in HTE adults living with HIV-1 and was generally well tolerated.</p><p><strong>Clinicaltrialsgov: </strong>NCT04233216.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"189-197"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12746772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
No cause for complacency regarding health of children who are HIV-exposed but uninfected. 对于接触艾滋病毒但未受感染的儿童的健康,没有理由自满。
IF 3.1 2区 医学 Q3 IMMUNOLOGY Pub Date : 2026-02-01 Epub Date: 2025-12-24 DOI: 10.1097/QAD.0000000000004394
Louise Kuhn, Alana T Brennan
{"title":"No cause for complacency regarding health of children who are HIV-exposed but uninfected.","authors":"Louise Kuhn, Alana T Brennan","doi":"10.1097/QAD.0000000000004394","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004394","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"40 2","pages":"249-251"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations of repeated measures of plasma biomarkers of kidney tubular health with longitudinal kidney function in people with HIV. HIV感染者肾小管健康血浆生物标志物重复测量与纵向肾功能的关系
IF 3.1 2区 医学 Q3 IMMUNOLOGY Pub Date : 2026-02-01 Epub Date: 2025-09-23 DOI: 10.1097/QAD.0000000000004359
Molly C Fisher, Rebecca Scherzer, Merve Postalcioglu, Teresa K Chen, Simon B Ascher, Jordan E Lake, Michelle Floris-Morre, Seble Kassaye, Igho Ofotokun, Jodie Dionne, Maria Alcaide, Mardge Cohen, Deborah Gustafson, Alison G Abraham, Joseph B Margolick, Ken Ho, Valentina Stosor, Phyllis C Tien, Michael Shlipak, Michelle M Estrella

Background: In people with HIV (PWH), urine tubular biomarkers have been linked to kidney function decline, but urine concentration variability limits their clinical utility. Plasma biomarkers may offer more stable indicators of kidney tubular health.

Methods: We conducted a case-cohort study of 440 PWH from the Multicenter AIDS Cohort Study (MACS)/Women's Interagency HIV Study (WIHS) Combined Cohort Study (MWCCS). Cases developed rapid kidney function decline [RKFD: ≥30% estimated glomerular filtration rate (eGFR) reduction]. We measured plasma biomarkers of tubular injury [kidney injury molecule-1 (KIM-1)], inflammation [tumor necrosis factor receptor-1 (TNFr1) and tumor necrosis factor receptor-2 (TNFr2)], and synthetic function [uromodulin (UMOD) and epidermal growth factor (EGF)] at baseline and year 2. Associations with RKFD were assessed using multivariable risk regression, adjusting for chronic kidney disease (CKD) and HIV-related risk factors, eGFR, and albuminuria. In a random sub-cohort, linear mixed models evaluated associations with annualized eGFR change.

Results: At baseline, median age was 49 years; 33% were women; 69% were virally suppressed; eGFR was similar in cases vs. noncases (93 vs. 94 ml/min/1.73 m 2 ). Over a median of 4.5 years, 172 RKFD events occurred. Each 1-standard deviation higher baseline KIM-1, TNFr1, TNFr2, UMOD, and EGF level was associated with adjusted relative risks (RR) for RKFD of 1.26 [95% confidence interval (CI): 1.15-1.39], 1.39 (1.24-1.55), 1.40 (1.24-1.57), 0.84 (0.77-0.93), and 0.85 (0.78-0.92), respectively. Findings were similar at year 2 and for 2-year biomarker changes. In joint models, baseline KIM-1, TNFr2, and UMOD remained independently associated with RKFD [RR: 1.19 (1.08-1.31), 1.27 (1.12-1.43), and 0.86 (0.78-0.95)], respectively. No biomarker was associated with annualized eGFR change in the sub-cohort.

Conclusion: In PWH, plasma biomarkers reflecting impaired kidney tubular health were independently associated with RKFD and may be useful prognosticators of adverse kidney outcomes.

背景:在HIV感染者(PWH)中,尿管生物标志物与肾功能下降有关,但尿浓度变异性限制了其临床应用。血浆生物标志物可能提供更稳定的肾小管健康指标。方法:我们对来自MACS/WIHS联合队列研究的440例PWH进行了病例队列研究。患者肾功能迅速下降(RKFD: eGFR降低≥30%)。我们在基线和第2年测量了血浆小管损伤(KIM-1)、炎症(TNFr1、TNFr2)和合成功能(UMOD、EGF)的生物标志物。使用多变量风险回归评估与RKFD的关联,调整CKD和hiv相关风险因素、eGFR和蛋白尿。在一个随机亚队列中,线性混合模型评估了与年化eGFR变化的关系。结果:基线时,中位年龄为49岁;33%是女性;69%的病毒被抑制;eGFR在病例和非病例中相似(93和94 mL/min/1.73m2)。在平均4.5年的时间里,发生了172例RKFD事件。基线KIM-1、TNFr1、TNFr2、UMOD和EGF水平每提高1个标准差,RKFD的调整相对危险度(RR)分别为1.26 (95%CI: 1.15-1.39)、1.39(1.24-1.55)、1.40(1.24-1.57)、0.84(0.77-0.93)和0.85(0.78-0.92)。第2年和第2年生物标志物变化的结果相似。在联合模型中,基线KIM-1、TNFr2和UMOD仍与RKFD独立相关(RR分别为1.19[1.08-1.31]、1.27[1.12-1.43]和0.86[0.78-0.95])。在亚队列中,没有生物标志物与年化eGFR变化相关。结论:在PWH中,反映肾小管健康受损的血浆生物标志物与RKFD独立相关,可能是肾脏不良结局的有用预后指标。
{"title":"Associations of repeated measures of plasma biomarkers of kidney tubular health with longitudinal kidney function in people with HIV.","authors":"Molly C Fisher, Rebecca Scherzer, Merve Postalcioglu, Teresa K Chen, Simon B Ascher, Jordan E Lake, Michelle Floris-Morre, Seble Kassaye, Igho Ofotokun, Jodie Dionne, Maria Alcaide, Mardge Cohen, Deborah Gustafson, Alison G Abraham, Joseph B Margolick, Ken Ho, Valentina Stosor, Phyllis C Tien, Michael Shlipak, Michelle M Estrella","doi":"10.1097/QAD.0000000000004359","DOIUrl":"10.1097/QAD.0000000000004359","url":null,"abstract":"<p><strong>Background: </strong>In people with HIV (PWH), urine tubular biomarkers have been linked to kidney function decline, but urine concentration variability limits their clinical utility. Plasma biomarkers may offer more stable indicators of kidney tubular health.</p><p><strong>Methods: </strong>We conducted a case-cohort study of 440 PWH from the Multicenter AIDS Cohort Study (MACS)/Women's Interagency HIV Study (WIHS) Combined Cohort Study (MWCCS). Cases developed rapid kidney function decline [RKFD: ≥30% estimated glomerular filtration rate (eGFR) reduction]. We measured plasma biomarkers of tubular injury [kidney injury molecule-1 (KIM-1)], inflammation [tumor necrosis factor receptor-1 (TNFr1) and tumor necrosis factor receptor-2 (TNFr2)], and synthetic function [uromodulin (UMOD) and epidermal growth factor (EGF)] at baseline and year 2. Associations with RKFD were assessed using multivariable risk regression, adjusting for chronic kidney disease (CKD) and HIV-related risk factors, eGFR, and albuminuria. In a random sub-cohort, linear mixed models evaluated associations with annualized eGFR change.</p><p><strong>Results: </strong>At baseline, median age was 49 years; 33% were women; 69% were virally suppressed; eGFR was similar in cases vs. noncases (93 vs. 94 ml/min/1.73 m 2 ). Over a median of 4.5 years, 172 RKFD events occurred. Each 1-standard deviation higher baseline KIM-1, TNFr1, TNFr2, UMOD, and EGF level was associated with adjusted relative risks (RR) for RKFD of 1.26 [95% confidence interval (CI): 1.15-1.39], 1.39 (1.24-1.55), 1.40 (1.24-1.57), 0.84 (0.77-0.93), and 0.85 (0.78-0.92), respectively. Findings were similar at year 2 and for 2-year biomarker changes. In joint models, baseline KIM-1, TNFr2, and UMOD remained independently associated with RKFD [RR: 1.19 (1.08-1.31), 1.27 (1.12-1.43), and 0.86 (0.78-0.95)], respectively. No biomarker was associated with annualized eGFR change in the sub-cohort.</p><p><strong>Conclusion: </strong>In PWH, plasma biomarkers reflecting impaired kidney tubular health were independently associated with RKFD and may be useful prognosticators of adverse kidney outcomes.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"160-169"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infectious morbidity among children HIV-exposed uninfected in South Africa. 南非暴露于艾滋病毒的未感染儿童的传染性发病率:婴儿期风险升高,但此后没有。
IF 3.1 2区 医学 Q3 IMMUNOLOGY Pub Date : 2026-02-01 Epub Date: 2025-09-23 DOI: 10.1097/QAD.0000000000004358
Kim Anderson, Hlengiwe P Madlala, Dorothy C Nyemba, Ryan Dinkele, Mariette Smith, Brian S Eley, Mark F Cotton, Rudzani Muloiwa, Graeme Spittal, Max Kroon, Andrew Boulle, Landon Myer, Mary-Ann Davies, Emma Kalk

Background: Increased risk of infectious morbidity and hospitalization has been reported during infancy among children HIV-exposed uninfected (CHEU) compared to children HIV-unexposed uninfected (CHUU). However, data on risks beyond infancy are limited.

Methods: We enrolled pregnant women with and without HIV from a primary healthcare facility in a lower income area in Cape Town, South Africa (2017-2018). We tracked their children's HIV test results and hospitalizations using routine electronic healthcare data. We previously reported increased rates of infectious-cause hospitalization among CHEU in the first year of life, and now extend the analysis to cover the period from age 1 to less than 5 years. Using random-effects Poisson regression, we calculated adjusted incidence rate ratios (aIRR) for infectious-cause hospitalization among CHEU vs. CHUU, clustered by infant and adjusted for child sex and vaccination status, maternal age and education, and housing type.

Results: Among 446 CHEU and 455 CHUU, 147 admissions occurred from age 1 to less than 5  years; with 59% ( n  = 87) due to infections. All-cause hospitalization occurred in 9.2% of CHEU and 10.5% of CHUU; infectious-cause hospitalization occurred in 6.5% of CHEU and 7.3% of CHUU with crude incidence rates of 2.4 per 100 child-years for both groups [IRR = 1.0; 95% confidence interval (CI) 0.6-1.6]. Adjusted analyses showed no evidence of increased hospitalization among CHEU (aIRR = 0.71; 95% CI 0.36-1.41).

Conclusion: Elevated risk of infectious-cause hospitalization among CHEU did not persist beyond the first year of life. These findings highlight infancy as a key window for targeted interventions, while providing reassurance regarding longer term infectious morbidity risk.

背景:据报道,与未接触艾滋病毒的未感染儿童(CHUU)相比,未接触艾滋病毒的未感染儿童(CHEU)在婴儿期感染发病率和住院风险增加。然而,关于婴儿期以外风险的数据有限。方法:我们招募了来自南非开普敦低收入地区初级卫生保健机构的感染和未感染艾滋病毒的孕妇(2017-2018年)。我们使用常规电子医疗数据跟踪他们孩子的HIV检测结果和住院情况。我们之前报道了CHEU在出生后一年内感染原因住院率的增加,现在将分析扩展到从1岁到1岁这段时间。结果:在446名CHEU和455名CHUU中,147名CHEU在出生后一年内入院。这些发现强调了婴儿期是有针对性干预的关键窗口,同时为长期感染发病率风险提供了保证。
{"title":"Infectious morbidity among children HIV-exposed uninfected in South Africa.","authors":"Kim Anderson, Hlengiwe P Madlala, Dorothy C Nyemba, Ryan Dinkele, Mariette Smith, Brian S Eley, Mark F Cotton, Rudzani Muloiwa, Graeme Spittal, Max Kroon, Andrew Boulle, Landon Myer, Mary-Ann Davies, Emma Kalk","doi":"10.1097/QAD.0000000000004358","DOIUrl":"10.1097/QAD.0000000000004358","url":null,"abstract":"<p><strong>Background: </strong>Increased risk of infectious morbidity and hospitalization has been reported during infancy among children HIV-exposed uninfected (CHEU) compared to children HIV-unexposed uninfected (CHUU). However, data on risks beyond infancy are limited.</p><p><strong>Methods: </strong>We enrolled pregnant women with and without HIV from a primary healthcare facility in a lower income area in Cape Town, South Africa (2017-2018). We tracked their children's HIV test results and hospitalizations using routine electronic healthcare data. We previously reported increased rates of infectious-cause hospitalization among CHEU in the first year of life, and now extend the analysis to cover the period from age 1 to less than 5 years. Using random-effects Poisson regression, we calculated adjusted incidence rate ratios (aIRR) for infectious-cause hospitalization among CHEU vs. CHUU, clustered by infant and adjusted for child sex and vaccination status, maternal age and education, and housing type.</p><p><strong>Results: </strong>Among 446 CHEU and 455 CHUU, 147 admissions occurred from age 1 to less than 5  years; with 59% ( n  = 87) due to infections. All-cause hospitalization occurred in 9.2% of CHEU and 10.5% of CHUU; infectious-cause hospitalization occurred in 6.5% of CHEU and 7.3% of CHUU with crude incidence rates of 2.4 per 100 child-years for both groups [IRR = 1.0; 95% confidence interval (CI) 0.6-1.6]. Adjusted analyses showed no evidence of increased hospitalization among CHEU (aIRR = 0.71; 95% CI 0.36-1.41).</p><p><strong>Conclusion: </strong>Elevated risk of infectious-cause hospitalization among CHEU did not persist beyond the first year of life. These findings highlight infancy as a key window for targeted interventions, while providing reassurance regarding longer term infectious morbidity risk.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"170-177"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12614741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic review of models used to estimate undiagnosed HIV prevalence in high-income low-prevalence countries and territories. 对用于估计高收入低流行国家和地区未确诊艾滋病毒流行率的模型进行系统审查。
IF 3.1 2区 医学 Q3 IMMUNOLOGY Pub Date : 2026-02-01 Epub Date: 2025-10-22 DOI: 10.1097/QAD.0000000000004390
Julia Scott, Andrew Anglemyer, Jason J Ong, Zoe Kumbaroff, Peter Saxton

Introduction: Estimating undiagnosed HIV prevalence facilitates planning epidemic responses, and monitoring progress towards UNAIDS and national targets. We undertook a systematic review to identify models used to estimate undiagnosed HIV prevalence in overall populations in high-income low-HIV-prevalence countries and territories to inform model selection in New Zealand.

Methods: We searched Medline, EMBASE, Web of Science, CINAHL and Cochrane Database of Systematic Reviews to 5 March 2025. Two authors independently reviewed studies with conflicts resolved by a third. We assessed study quality against five key characteristics of good modelling practice. We undertook a grey literature search to identify modelling in HIV surveillance or monitoring reports.

Results: We identified 2147 unique citations, with 119 full text studies retrieved and 48 included. Forty-six studies described modelling undiagnosed HIV prevalence in 23 countries and territories, a further two for multiple countries. The most common methods used CD4 + back-calculation, with the ECDC model most frequently used (10 studies), followed by a clinical stage-based back-calculation model, a CD4 + depletion model and the Spectrum CSAVR model (eight, four and three studies, respectively). Almost all studies noted a full mathematical model description, included parameters, validation and uncertainty estimates. Only five articles estimated undiagnosed HIV by ethnicity, but estimates by gender and exposure were common.

Conclusion: CD4 + back-calculation models, notably the online accessible ECDC model, have been most commonly used. These are well suited to surveillance systems like New Zealand's, which collect demographic and exposure details and CD4 + cell counts at HIV diagnosis, but limited exposure group size and seroprevalence information.

导言:估计未确诊的艾滋病毒流行率有助于规划流行病应对措施,并监测实现艾滋病规划署和国家目标的进展情况。我们进行了一项系统综述,以确定用于估计高收入低艾滋病流行国家和地区总体人群中未确诊的艾滋病流行率的模型,为新西兰的模型选择提供信息。方法:检索Medline、EMBASE、Web of Science、CINAHL、Cochrane系统评价数据库至2025年3月5日。两位作者独立审查了由第三方解决冲突的研究。我们根据良好建模实践的五个关键特征评估了研究质量。我们进行了灰色文献检索,以确定艾滋病毒监测或监测报告中的模型。结果:我们确定了2147条独特引用,检索到119篇全文研究,其中48篇被收录。46项研究对23个国家和地区未确诊的艾滋病毒流行情况进行了建模,另外两项研究对多个国家进行了建模。最常见的方法是使用CD4反向计算,其中最常用的是ECDC模型(10项研究),其次是基于临床阶段的反向计算模型、CD4耗竭模型和Spectrum CSAVR模型(分别为8项、4项和3项研究)。几乎所有的研究都有完整的数学模型描述,包括参数、验证和不确定性估计。只有5篇论文按种族估计了未确诊的艾滋病毒,但按性别和暴露程度估计是常见的。结论:CD4回算模型,特别是在线可访问的ECDC模型是最常用的。这些非常适合像新西兰这样的监测系统,这些系统在艾滋病毒诊断时收集人口统计和暴露细节以及CD4计数,但有限的暴露组规模和血清阳性率信息。
{"title":"A systematic review of models used to estimate undiagnosed HIV prevalence in high-income low-prevalence countries and territories.","authors":"Julia Scott, Andrew Anglemyer, Jason J Ong, Zoe Kumbaroff, Peter Saxton","doi":"10.1097/QAD.0000000000004390","DOIUrl":"10.1097/QAD.0000000000004390","url":null,"abstract":"<p><strong>Introduction: </strong>Estimating undiagnosed HIV prevalence facilitates planning epidemic responses, and monitoring progress towards UNAIDS and national targets. We undertook a systematic review to identify models used to estimate undiagnosed HIV prevalence in overall populations in high-income low-HIV-prevalence countries and territories to inform model selection in New Zealand.</p><p><strong>Methods: </strong>We searched Medline, EMBASE, Web of Science, CINAHL and Cochrane Database of Systematic Reviews to 5 March 2025. Two authors independently reviewed studies with conflicts resolved by a third. We assessed study quality against five key characteristics of good modelling practice. We undertook a grey literature search to identify modelling in HIV surveillance or monitoring reports.</p><p><strong>Results: </strong>We identified 2147 unique citations, with 119 full text studies retrieved and 48 included. Forty-six studies described modelling undiagnosed HIV prevalence in 23 countries and territories, a further two for multiple countries. The most common methods used CD4 + back-calculation, with the ECDC model most frequently used (10 studies), followed by a clinical stage-based back-calculation model, a CD4 + depletion model and the Spectrum CSAVR model (eight, four and three studies, respectively). Almost all studies noted a full mathematical model description, included parameters, validation and uncertainty estimates. Only five articles estimated undiagnosed HIV by ethnicity, but estimates by gender and exposure were common.</p><p><strong>Conclusion: </strong>CD4 + back-calculation models, notably the online accessible ECDC model, have been most commonly used. These are well suited to surveillance systems like New Zealand's, which collect demographic and exposure details and CD4 + cell counts at HIV diagnosis, but limited exposure group size and seroprevalence information.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"227-238"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12746781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145342547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paradoxical tuberculosis-immune reconstitution inflammatory response syndrome after antituberculous drug modification in HIV with dual central nervous system infections. 双重中枢神经系统感染的HIV患者抗结核药物修饰后的矛盾结核-免疫重建炎症反应综合征。
IF 3.1 2区 医学 Q3 IMMUNOLOGY Pub Date : 2026-02-01 Epub Date: 2025-12-24 DOI: 10.1097/QAD.0000000000004398
Shrreya Agarawal, Joydeep Samanta, Richa Singh Chauhan, Nihar Kathrani, Saravana Sukriya, Jhasaketan Meher, Vinay R Pandit
{"title":"Paradoxical tuberculosis-immune reconstitution inflammatory response syndrome after antituberculous drug modification in HIV with dual central nervous system infections.","authors":"Shrreya Agarawal, Joydeep Samanta, Richa Singh Chauhan, Nihar Kathrani, Saravana Sukriya, Jhasaketan Meher, Vinay R Pandit","doi":"10.1097/QAD.0000000000004398","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004398","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"40 2","pages":"267-269"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elevated sCD14 in cerebrospinal fluid: a surrogate marker for HIV-associated neurocognitive disorders in Brazil. 脑脊液sCD14升高:巴西hiv相关神经认知障碍的替代标志物
IF 3.1 2区 医学 Q3 IMMUNOLOGY Pub Date : 2026-02-01 Epub Date: 2025-12-24 DOI: 10.1097/QAD.0000000000004368
Carlos F Apoliano, Ana C S de Oliveira, Víctor  Folgosi, Gabriela S Prates, Maria R Gascon, José E Vidal, Jerusa Smid, Rosa M do N Marcusso, Augusto C Penalva, Youyang Tang, Guochun Jiang, Camila M Romano, Jorge Casseb

This study investigates cerebrospinal fluid (CSF) biomarkers associated with HIV-associated neurocognitive disorders (HAND) in people with HIV (PWH) in Brazil. Among 79 HIV-positive participants and 7 negative controls, elevated levels of inflammatory cytokines and soluble CD14 (sCD14) were found. The sCD14 showed promise as a diagnostic marker, and combined with other proinflammatory markers, may improve early detection and monitoring of HAND.

本研究调查了巴西HIV感染者(PWH)中与HIV相关神经认知障碍(HAND)相关的脑脊液(CSF)生物标志物。在79名hiv阳性参与者和7名阴性对照中,发现炎症细胞因子和可溶性CD14 (sCD14)水平升高。sCD14有望作为一种诊断标志物,并与其他促炎标志物联合使用,可改善HAND的早期检测和监测。
{"title":"Elevated sCD14 in cerebrospinal fluid: a surrogate marker for HIV-associated neurocognitive disorders in Brazil.","authors":"Carlos F Apoliano, Ana C S de Oliveira, Víctor  Folgosi, Gabriela S Prates, Maria R Gascon, José E Vidal, Jerusa Smid, Rosa M do N Marcusso, Augusto C Penalva, Youyang Tang, Guochun Jiang, Camila M Romano, Jorge Casseb","doi":"10.1097/QAD.0000000000004368","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004368","url":null,"abstract":"<p><p>This study investigates cerebrospinal fluid (CSF) biomarkers associated with HIV-associated neurocognitive disorders (HAND) in people with HIV (PWH) in Brazil. Among 79 HIV-positive participants and 7 negative controls, elevated levels of inflammatory cytokines and soluble CD14 (sCD14) were found. The sCD14 showed promise as a diagnostic marker, and combined with other proinflammatory markers, may improve early detection and monitoring of HAND.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"40 2","pages":"260-263"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and risk factors of cognitive frailty in people with HIV. 艾滋病毒感染者认知衰弱的患病率和危险因素。
IF 3.1 2区 医学 Q3 IMMUNOLOGY Pub Date : 2026-02-01 Epub Date: 2025-11-24 DOI: 10.1097/QAD.0000000000004352
Jovana Milic, Stefano Calza, Luca Lazzarini, Mattia Cocchi, Federico Motta, Stefano Renzetti, Laura Sighinolfi, Michela Belli, Vera Todisco, Maddalena Albertini, Altea Gallerani, Marianna Menozzi, Gianluca Cuomo, Giuseppe Mancini, Chiara Mussi, Cristina Mussini, Andrea Calcagno, Giovanni Guaraldi

Background: Cognitive frailty (CF, the simultaneous presence of frailty and cognitive impairment) is recognized as a significant predictor of several adverse health outcomes. The objective of this study was to describe prevalence and risk factors for CF in people with HIV (PWH) >50  years.

Methods: This was a cross-sectional observational study including PWH attending Modena HIV Metabolic Clinic (MHMC). Neurocognitive function was measured with Cogstate battery that comprises six domains. Each individual CogState raw score was transformed into z-score after correction for age and sex. Neurocognitive impairment was defined by total global deficit score >0.5. Frailty was assessed by 37-Item frailty index. Scores <0.25 were considered fit or >0.26 as frail.

Results: A total of 1258 PWH were included, 916 (73%) were males, median age was 58 years, median time since HIV diagnosis was 27 years. The sample was divided into four groups (CF) based on the presence of frailty (F) and cognitive impairment (ICT): F+/ICT+, F+/ICT-, F-/ICT+, F-/ICT-. Age per 5-year increase [odds ratio (OR) = 1.27, confidence interval (CI): 1.02-1.55, P  = 0.022], nadir CD4 + cell count (OR = 0.81, CI: 0.66 - 0.99, P  = 0.042) and polypharmacy (OR = 3.47, CI: 2.00-6.00, P < 0.001) were associated with CF after adjustment for time since HIV diagnosis, multimorbidity, depression and cumulative exposure to dolutegravir.

Conclusion: CF prevalence in PWH >50 years was 6.8% and it is higher than what has been observed in the general population >65 years (1-4.4%). Nadir CD4 + cell count and polypharmacy was associated with CF, suggesting an HIV specific contribution related to the development of this condition.

背景:认知衰弱(CF,同时存在的衰弱和认知障碍)被认为是一些不良健康结果的重要预测因子。本研究的目的是描述50岁以下HIV感染者(PWH) CF的患病率和危险因素。方法:这是一项横断面观察研究,包括在摩德纳HIV代谢诊所(MHMC)就诊的PWH。神经认知功能用Cogstate电池测量。每个个体的CogState原始分数经过年龄和性别校正后转化为z分数。神经认知障碍的定义为全球总缺陷评分>0.5。采用37项衰弱指数评价。虚弱的得分为0.26。结果:共纳入1258例PWH,其中男性916例(73%),中位年龄58岁,中位诊断时间27年。根据虚弱(F)和认知障碍(ICT)的存在将样本分为四组(CF): F + /ICT +, F + /ICT-, F-/ICT +, F-/ICT-。每5年增加的年龄(OR = 1.27, CI: 1.02-1.55, p = 0.022),最低CD4细胞计数(OR = 0.81, CI: 0.66 - 0.99, p = 0.042)和多药治疗(OR = 3.47, CI: 2.00 - 6.00, p)结论:PWH患者50岁的CF患病率为6.8%,高于普通人群65岁的患病率(1-4.4%)。最低CD4细胞计数和多药与CF有关,提示HIV特异性贡献与该疾病的发展有关。
{"title":"Prevalence and risk factors of cognitive frailty in people with HIV.","authors":"Jovana Milic, Stefano Calza, Luca Lazzarini, Mattia Cocchi, Federico Motta, Stefano Renzetti, Laura Sighinolfi, Michela Belli, Vera Todisco, Maddalena Albertini, Altea Gallerani, Marianna Menozzi, Gianluca Cuomo, Giuseppe Mancini, Chiara Mussi, Cristina Mussini, Andrea Calcagno, Giovanni Guaraldi","doi":"10.1097/QAD.0000000000004352","DOIUrl":"10.1097/QAD.0000000000004352","url":null,"abstract":"<p><strong>Background: </strong>Cognitive frailty (CF, the simultaneous presence of frailty and cognitive impairment) is recognized as a significant predictor of several adverse health outcomes. The objective of this study was to describe prevalence and risk factors for CF in people with HIV (PWH) >50  years.</p><p><strong>Methods: </strong>This was a cross-sectional observational study including PWH attending Modena HIV Metabolic Clinic (MHMC). Neurocognitive function was measured with Cogstate battery that comprises six domains. Each individual CogState raw score was transformed into z-score after correction for age and sex. Neurocognitive impairment was defined by total global deficit score >0.5. Frailty was assessed by 37-Item frailty index. Scores <0.25 were considered fit or >0.26 as frail.</p><p><strong>Results: </strong>A total of 1258 PWH were included, 916 (73%) were males, median age was 58 years, median time since HIV diagnosis was 27 years. The sample was divided into four groups (CF) based on the presence of frailty (F) and cognitive impairment (ICT): F+/ICT+, F+/ICT-, F-/ICT+, F-/ICT-. Age per 5-year increase [odds ratio (OR) = 1.27, confidence interval (CI): 1.02-1.55, P  = 0.022], nadir CD4 + cell count (OR = 0.81, CI: 0.66 - 0.99, P  = 0.042) and polypharmacy (OR = 3.47, CI: 2.00-6.00, P < 0.001) were associated with CF after adjustment for time since HIV diagnosis, multimorbidity, depression and cumulative exposure to dolutegravir.</p><p><strong>Conclusion: </strong>CF prevalence in PWH >50 years was 6.8% and it is higher than what has been observed in the general population >65 years (1-4.4%). Nadir CD4 + cell count and polypharmacy was associated with CF, suggesting an HIV specific contribution related to the development of this condition.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"133-142"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12746784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145090982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimated major adverse cardiovascular events averted among persons with HIV if treated with a moderate-intensity statin. 估计如果用中等强度的他汀类药物治疗,HIV感染者可避免主要不良心血管事件。
IF 3.1 2区 医学 Q3 IMMUNOLOGY Pub Date : 2026-02-01 Epub Date: 2025-10-15 DOI: 10.1097/QAD.0000000000004385
Kathy K Byrd, Yunfeng Tie, Carol Yen-Chin Lin, Yishiow Kuo, Linda Beer, Siobhan M O'Connor, Kate Buchacz, Feijun Luo, John Weiser

Objective: To estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk among US adults with diagnosed HIV (PWH) and number of first major adverse cardiovascular events (MACE) that are potentially preventable over a 5-year period, if US Department of Health and Human Services recommendations for statin therapy for PWH were fully implemented.

Design: Cross-sectional study of nationally representative, individual-level data on behavioral and clinical characteristics of US PWH.

Methods: Using data from standardized questionnaires and medical records abstraction collected from June 2022 to May 2023, we calculated weighted estimates of the following among PWH aged 40-75 years without documented cardiovascular disease ( N  = 2155): 10-year ASCVD risk; statin prescription by risk level; number potentially avoidable first MACE over 5 years with moderate-intensity statin treatment. We used the 2013 Pooled Cohort Equation to calculate ASCVD risk. MACE averted was estimated by applying the 5-year number needed to treat, from the REPRIEVE trial North American cohort, to the weighted number of PWH eligible for statin therapy.

Results: Among PWH eligible for therapy, 72.5% were male individuals, 42.5% were aged 50-59 years and 35.9% were Black, non-Hispanic persons. The overall median risk score was 7.1% [95% confidence interval (CI): 6.8-7.4%]. Among those with low (<5%) and moderate risk (5 to <20%), 19.8% (16.7-22.9%) and 36.9% (33.4-40.4%) were on statin therapy, respectively. An estimated 7418 (95% CI: 1116 -13 909) additional first MACE could be prevented over 5 years if eligible PWH received moderate-intensity statin therapy.

Conclusion: Fully implementing statin therapy recommendations for PWH in the United States could substantially reduce MACE among this population.

目的:如果美国卫生和人类服务部对他汀类药物治疗PWH的建议得到全面实施,估计美国成年HIV (PWH)患者10年动脉粥样硬化性心血管疾病(ASCVD)的风险和5年期间潜在可预防的第一主要心血管不良事件(MACE)的数量。设计:对美国PWH患者的行为和临床特征进行具有全国代表性的个人数据横断面研究。方法:利用从2022年6月至2023年5月收集的标准化问卷和医疗记录摘录的数据,我们计算了40-75岁无心血管疾病的PWH (N = 2155)的以下加权估计:10年ASCVD风险;风险等级的他汀类药物处方;中等强度他汀类药物治疗5年内可能避免的首次MACE数量。我们使用2013年合并队列方程来计算ASCVD风险。通过将先前公布的治疗所需的5年数字应用于符合他汀类药物治疗的PWH加权数来估计避免的MACE。结果:在符合治疗条件的PWH患者中,72.5%为男性,42.5%年龄在50-59岁之间,35.9%为黑人,非西班牙裔。总体中位风险评分为7.1%(95%可信区间[CI]: 6.8%-7.4%)。结论:在美国全面实施他汀类药物治疗可显著降低该人群的MACE。
{"title":"Estimated major adverse cardiovascular events averted among persons with HIV if treated with a moderate-intensity statin.","authors":"Kathy K Byrd, Yunfeng Tie, Carol Yen-Chin Lin, Yishiow Kuo, Linda Beer, Siobhan M O'Connor, Kate Buchacz, Feijun Luo, John Weiser","doi":"10.1097/QAD.0000000000004385","DOIUrl":"10.1097/QAD.0000000000004385","url":null,"abstract":"<p><strong>Objective: </strong>To estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk among US adults with diagnosed HIV (PWH) and number of first major adverse cardiovascular events (MACE) that are potentially preventable over a 5-year period, if US Department of Health and Human Services recommendations for statin therapy for PWH were fully implemented.</p><p><strong>Design: </strong>Cross-sectional study of nationally representative, individual-level data on behavioral and clinical characteristics of US PWH.</p><p><strong>Methods: </strong>Using data from standardized questionnaires and medical records abstraction collected from June 2022 to May 2023, we calculated weighted estimates of the following among PWH aged 40-75 years without documented cardiovascular disease ( N  = 2155): 10-year ASCVD risk; statin prescription by risk level; number potentially avoidable first MACE over 5 years with moderate-intensity statin treatment. We used the 2013 Pooled Cohort Equation to calculate ASCVD risk. MACE averted was estimated by applying the 5-year number needed to treat, from the REPRIEVE trial North American cohort, to the weighted number of PWH eligible for statin therapy.</p><p><strong>Results: </strong>Among PWH eligible for therapy, 72.5% were male individuals, 42.5% were aged 50-59 years and 35.9% were Black, non-Hispanic persons. The overall median risk score was 7.1% [95% confidence interval (CI): 6.8-7.4%]. Among those with low (<5%) and moderate risk (5 to <20%), 19.8% (16.7-22.9%) and 36.9% (33.4-40.4%) were on statin therapy, respectively. An estimated 7418 (95% CI: 1116 -13 909) additional first MACE could be prevented over 5 years if eligible PWH received moderate-intensity statin therapy.</p><p><strong>Conclusion: </strong>Fully implementing statin therapy recommendations for PWH in the United States could substantially reduce MACE among this population.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"204-214"},"PeriodicalIF":3.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12802393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145298016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
AIDS
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1